Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Hepatitis Breakthrough | Vir Biotechnology's promising Phase 2 results in chronic hepatitis delta and B treatments position it as a potential market leader in addressing unmet medical needs |
Financial Crossroads | Despite a strong cash position, Vir faces challenges with negative EBITDA and EPS estimates, balancing R&D investments against the path to profitability |
Pipeline Potential | Explore Vir's diverse portfolio, including viral hepatitis programs and T-cell engagers, with peak revenue estimates exceeding $10 billion annually |
Market Valuation | Analyst price targets range from $10 to $110 per share, reflecting varied perspectives on Vir's growth potential amid clinical advancements and market opportunities |
Metrics to compare | VIR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVIRPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −9.3x | −0.5x | |
PEG Ratio | 0.24 | −0.06 | 0.00 | |
Price/Book | 0.7x | 1.3x | 2.6x | |
Price / LTM Sales | 34.7x | 4.0x | 3.0x | |
Upside (Analyst Target) | 196.4% | 238.5% | 52.4% | |
Fair Value Upside | Unlock | 43.0% | 8.7% | Unlock |